Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash from Investing Activities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Cash from Investing Activities for 15 consecutive years, with -$3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 36.78% to -$3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$216.4 million, a 1316.61% decrease, with the full-year FY2024 number at -$213.1 million, down 1679.46% from a year prior.
  • Cash from Investing Activities was -$3.2 million for Q3 2025 at Usana Health Sciences, up from -$4.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $179000.0 in Q3 2023 to a low of -$205.1 million in Q4 2024.
  • A 5-year average of -$14.9 million and a median of -$3.3 million in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 104.81% in 2023, then crashed 2701.67% in 2024.
  • Usana Health Sciences' Cash from Investing Activities stood at -$3.1 million in 2021, then decreased by 6.28% to -$3.3 million in 2022, then tumbled by 123.1% to -$7.3 million in 2023, then plummeted by 2701.67% to -$205.1 million in 2024, then soared by 98.44% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Cash from Investing Activities are -$3.2 million (Q3 2025), -$4.2 million (Q2 2025), and -$3.9 million (Q1 2025).